Dr Lal Pathlabs
-
{
- All
- News
- Videos
-
Dr Lal PathLabs Q1 Result: Net Profit Jumps 29% YoY, Revenue Rises 19%; Interim Dividend Declared — Check Record Date
At the operating level, earnings before interest, tax, depreciation and amortisation (EBITDA) climbed 28.7% to Rs 248 crore, compared with Rs 192 crore in the year-ago quarter.
-
Delhi Diagnostics Lab Sounds Caution Over Covid Testing Material Shortage
A large diagnostic chain has sounded caution over an impending shortage of material used in testing for COVID-19 amid a surge in cases across the country in what is now being called a deadly second wave.
-
Dr Lal Pathlabs Left Millions of Patients’ Sensitive Data on Public Server: Report
Australia-based security expert Sami Toivonen first discovered this sensitive data last month, and he immediately reported this lapse of security to Dr Lal PathLabs. While the company took the necessary measures to shut down access to the storage bucket, it did not respond to Toivonen. The spreadsheets contained sensitive information like patient n...
-
Nectar Lifesciences, Just Dial, IRCTC in Fortune India's 'Next 500' List
Just Dial, UTI Asset Management Company and IRCTC are among the firms that have made it to the Fortune Next 500 list of Indian companies, which has been topped by Dynamatic Technologies
-
Dr Lal PathLabs, Emami, Havells Among Citi's Top Midcap Bets
Citi's top midcap picks are Apollo Hospital, Container Corp, Dish TV, Dr Lal PathLabs, Emami, Exide, Federal Bank, GSPL, Havells India and Petronet.
-
Thyrocare Technologies IPO To Open On April 27
Diagnostics company Thyrocare Technologies will hit the capital markets on April 27 to raise funds through an initial public offering.
-
New Entrants Stay Afloat as Dalal Street Sinks Deep
A number of new entrants to the stock market this fiscal year have managed to stay above their IPO levels, even as some big names like Coffee Day Enterprises and InterGlobe Aviation have fallen sharply from their peaks.
-
Dr Lal PathLabs Q3 Profit More Than Doubles to Rs 61 Crore
Diagnostic services provider Dr Lal PathLabs on Saturday reported over two-fold jump in consolidated net profit at Rs 60.82 crore for the third quarter ended December 31, 2015.
-
IPO Drought Ends as Companies Raise Rs 13,600 Crore in 2015
Ending the IPO drought, 21 companies have entered Dalal Street in 2015 with initial public offers to garner Rs 13,600 crore - the highest in five years - and an impressive pipeline is already in place for the new year.
-
Buy Sun Pharma, Avoid Dr Lal PathLabs, Says Mayuresh Joshi
Mayuresh Joshi of Angel Broking says prices of some midcap stocks have run-up ahead of earnings expectations. Investors should buy banks, auto and select pharma names, while avoiding capital goods stocks, he added.
-
Dr Lal PathLabs to Enter New Geographies, Says CEO
Dr Lal PathLabs showcased a stellar listing on the stock exchanges today. Shares of Dr Lal PathLabs rallied as much as 42 per cent to hit high of Rs 783.45 on the National Stock Exchange against its issue price of Rs 550.
-
Dr Lal PathLabs Shares Soar Over 50% in Blockbuster Debut
Shares of diagnostic chain Dr Lal PathLabs jumped as much as 42 per cent on Wednesday in blockbuster debut. Dr Lal PathLabs shares rose to an intraday high of Rs 782 as compared to the issue price of Rs 550.
-
Dr Lal PathLabs Sees Blockbuster Listing, Stock up 31%
Shares of diagnostic chain Dr Lal PathLabs today listed with a strong premium of almost 31 per cent over the issue price of Rs 550.
-
Dr Lal PathLabs, Alkem Lab Soar Over 30% on Debut
Generics drugmaker Alkem Laboratories shares jumped nearly 33 per cent to hit a high of Rs 1,401. The company had raised Rs 1,350 crore in its initial public offering after pricing shares at Rs 1,050 each. Alkem Laboratories' IPO was subscribed 44.3 times.
-
Investors From Mumbai, Ahmedabad Dominate IPO Market in 2015
Individuals from Mumbai and Ahmedabad account for more than half of the funds garnered from retail investors in IPOs so far in 2015, while the national capital has contributed less than 6 per cent.
-
Dr Lal PathLabs Q1 Result: Net Profit Jumps 29% YoY, Revenue Rises 19%; Interim Dividend Declared — Check Record Date
At the operating level, earnings before interest, tax, depreciation and amortisation (EBITDA) climbed 28.7% to Rs 248 crore, compared with Rs 192 crore in the year-ago quarter.
-
Delhi Diagnostics Lab Sounds Caution Over Covid Testing Material Shortage
A large diagnostic chain has sounded caution over an impending shortage of material used in testing for COVID-19 amid a surge in cases across the country in what is now being called a deadly second wave.
-
Dr Lal Pathlabs Left Millions of Patients’ Sensitive Data on Public Server: Report
Australia-based security expert Sami Toivonen first discovered this sensitive data last month, and he immediately reported this lapse of security to Dr Lal PathLabs. While the company took the necessary measures to shut down access to the storage bucket, it did not respond to Toivonen. The spreadsheets contained sensitive information like patient n...
-
Nectar Lifesciences, Just Dial, IRCTC in Fortune India's 'Next 500' List
Just Dial, UTI Asset Management Company and IRCTC are among the firms that have made it to the Fortune Next 500 list of Indian companies, which has been topped by Dynamatic Technologies
-
Dr Lal PathLabs, Emami, Havells Among Citi's Top Midcap Bets
Citi's top midcap picks are Apollo Hospital, Container Corp, Dish TV, Dr Lal PathLabs, Emami, Exide, Federal Bank, GSPL, Havells India and Petronet.
-
Thyrocare Technologies IPO To Open On April 27
Diagnostics company Thyrocare Technologies will hit the capital markets on April 27 to raise funds through an initial public offering.
-
New Entrants Stay Afloat as Dalal Street Sinks Deep
A number of new entrants to the stock market this fiscal year have managed to stay above their IPO levels, even as some big names like Coffee Day Enterprises and InterGlobe Aviation have fallen sharply from their peaks.
-
Dr Lal PathLabs Q3 Profit More Than Doubles to Rs 61 Crore
Diagnostic services provider Dr Lal PathLabs on Saturday reported over two-fold jump in consolidated net profit at Rs 60.82 crore for the third quarter ended December 31, 2015.
-
IPO Drought Ends as Companies Raise Rs 13,600 Crore in 2015
Ending the IPO drought, 21 companies have entered Dalal Street in 2015 with initial public offers to garner Rs 13,600 crore - the highest in five years - and an impressive pipeline is already in place for the new year.
-
Buy Sun Pharma, Avoid Dr Lal PathLabs, Says Mayuresh Joshi
Mayuresh Joshi of Angel Broking says prices of some midcap stocks have run-up ahead of earnings expectations. Investors should buy banks, auto and select pharma names, while avoiding capital goods stocks, he added.
-
Dr Lal PathLabs to Enter New Geographies, Says CEO
Dr Lal PathLabs showcased a stellar listing on the stock exchanges today. Shares of Dr Lal PathLabs rallied as much as 42 per cent to hit high of Rs 783.45 on the National Stock Exchange against its issue price of Rs 550.
-
Dr Lal PathLabs Shares Soar Over 50% in Blockbuster Debut
Shares of diagnostic chain Dr Lal PathLabs jumped as much as 42 per cent on Wednesday in blockbuster debut. Dr Lal PathLabs shares rose to an intraday high of Rs 782 as compared to the issue price of Rs 550.
-
Dr Lal PathLabs Sees Blockbuster Listing, Stock up 31%
Shares of diagnostic chain Dr Lal PathLabs today listed with a strong premium of almost 31 per cent over the issue price of Rs 550.
-
Dr Lal PathLabs, Alkem Lab Soar Over 30% on Debut
Generics drugmaker Alkem Laboratories shares jumped nearly 33 per cent to hit a high of Rs 1,401. The company had raised Rs 1,350 crore in its initial public offering after pricing shares at Rs 1,050 each. Alkem Laboratories' IPO was subscribed 44.3 times.
-
Investors From Mumbai, Ahmedabad Dominate IPO Market in 2015
Individuals from Mumbai and Ahmedabad account for more than half of the funds garnered from retail investors in IPOs so far in 2015, while the national capital has contributed less than 6 per cent.
